Evonik   Report issue

For profit
Founded: Essen Germany (2007)
Status: No NME R&D (2007)

Organization Overview

First Clinical Trial
2022
NCT05279573
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Evonik Operations GmbH

Active Ingredients

Drugs in Other Trials (2)

Key: Evonik (1) Acquired (1)

omega-3 fatty acids (Omacor) (1 trial)

vitis vinifera (1 trial)

Indications

Overview

  • Highest Phase: Phase 0
  • # of Trials: 2
  • # of Trial APIs: 2